Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 9/20 | 0.52 |
| ▸ | TFPI | P10646 | 2/20 | 0.49 |
| ▸ | APLNR | P35414 | 4/20 | 0.49 |
| ▸ | NPY1R | P25929 | 1/20 | 0.49 |
| ▸ | NPY2R | P49146 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | REN | P00797 | 1/20 | 0.48 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.48 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | MC5R | P33032 | 1/20 | 0.48 |
| ▸ | MC3R | P41968 | 1/20 | 0.48 |
| ▸ | MC1R | Q01726 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15928124 | 0.95 | CXCR4 (0.50) | CXCR4TFPIAPLNRTLR2REN | |
| SCHEMBL5580530 | 0.92 | APLNR (0.52) | APLNRTLR2 | |
| SCHEMBL15935518 | 0.86 | CXCR4 (0.53) | CXCR4TFPIREN | |
| SCHEMBL10277277 | 0.82 | APLNR (0.52) | APLNR | |
| SCHEMBL29635486 | 0.77 | CXCR4 (0.73) | CXCR4NPY1RNPY2RNPY4RNPY5R | |
| Ghrelin SCHEMBL29350821 | 0.76 | TFPI (0.64) | CXCR4TFPINPY1RNPY2RNPY4R | |
| SCHEMBL29352758 | 0.76 | TLR2 (0.58) | TLR2 | |
| SCHEMBL29473717 | 0.75 | CALCR (0.57) | APLNR | |
| SCHEMBL27016689 | 0.74 | OPRD1 (0.52) | CXCR4RENMC4RMC5RMC3R | |
| SCHEMBL11305399 | 0.73 | TLR2 (0.43) | CXCR4APLNRTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 728 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312440-A1 | CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS | THE UNIVERSITY OF CHICAGO (US) | 2025-10-09 | — | — | US | claimed |
| US-12411208-B2 | Coherent microwave photonics radar detection method and system based on injection locking frequency multiplication | Zhejiang Lab (CN) | 2025-09-09 | — | — | US | claimed |
| US-20250275940-A1 | PTEROSTILBENE AND SILIBININ FOR PREVENTING, AMELIORATING OR REDUCING RADIATION-INDUCED DISEASES | FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE DE LA COMUNIDAD VALENCIANA (ES) | 2025-09-04 | — | — | US | claimed |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | NOVARTIS AG (CH) | 2025-07-03 | — | — | US | claimed |
| US-20250177303-A1 | A DRUG NANOCARRIER SYSTEM TO DELIVER A COMBINATION OF TLR AGONISTS AND/OR A LIPOXIN PLUS IMMUNOGENIC CELL DEATH INDUCING CHEMOTHERAPEUTIC AGENTS FOR CANCER IMMUNOTHERAPY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-05 | — | — | US | claimed |
| WO-2025089649-A1 | COMPOSITION FOR TRANSFERRING NUCLEIC ACIDS COMPRISING CATIONIC LIPOSOMES AND USES THEREOF | 주식회사 차백신연구소 | 2025-05-01 | — | — | WO | claimed |
| EP-4531910-A2 | CHEMICAL SCREEN OF MODULATORS FOR VACCINE ADJUVANTS | The University of Chicago (US) | 2025-04-09 | — | — | EP | claimed |
| WO-2025047993-A1 | ANTI-DOPPEL ANTIBODY DRUG CONJUGATES | PHAROSGEN CO., LTD. (KR) | 2025-03-06 | — | — | WO | claimed |
| EP-4277610-B1 | PTEROSTILBENE AND SILIBININ FOR PREVENTING, AMELIORATING OR REDUCING RADIATION-INDUCED DISEASES | UNIV VALENCIA (ES) | 2025-02-26 | — | — | EP | claimed |
| US-20250041352-A1 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | SPINALCYTE LLC (US) | 2025-02-06 | — | — | US | claimed |
| WO-2022152943-A1 | PTEROSTILBENE AND SILIBININ FOR PREVENTING, AMELIORATING OR REDUCING RADIATION-INDUCED DISEASES | UNIVERSITAT DE VALÈNCIA (ES) | 2022-07-21 | — | — | WO | claimed |
| EP-4029496-A1 | PTEROSTILBENE AND SILIBININ FOR PREVENTING, AMELIORATING OR REDUCING RADIATION-INDUCED DISEASES | Universitat de València (ES) | 2022-07-20 | — | — | EP | claimed |
| CN-111316151-B | Imaging lens, imaging device and electronic equipment | 深圳市大疆创新科技有限公司 | 2022-07-15 | — | — | CN | claimed |
| US-20220211866-A1 | MOMP TELONANOPARTICLES, AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | LAWRENCE LIVERMORE NATIONAL SECURITY, LLC | 2022-07-07 | — | — | US | claimed |
| WO-2022112558-A1 | APPLICATION OF STEM-CELL DERIVED MONOCYTES IN A MONOCYTE ACTIVATION TEST (MAT) FOR THE ASSESSMENT OF PYROGENICITY AND INFLAMMATORY POTENTIAL | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-06-02 | — | — | WO | claimed |
| EP-4006546-A1 | APPLICATION OF STEM-CELL DERIVED MONOCYTES IN A MONOCYTE ACTIVATION TEST (MAT) FOR THE ASSESSMENT OF PYROGENICITY AND INFLAMMATORY POTENTIAL | Medizinische Hochschule Hannover (DE) | 2022-06-01 | — | — | EP | claimed |
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | CHILDREN'S MEDICAL CENTER CORPORATION | 2022-05-05 | — | — | US | claimed |
| WO-2022047486-A2 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS | FIGENE, LLC (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2022026336-A1 | MODULATION OF ENDOPLASMIC RETICULUM AMINOPEPTIDASE 2 (ERAP2)-MEDIATED IMMUNE RESPONSE | REGENERON PHARMACEUTICALS, INC. (US) | 2022-02-03 | — | — | WO | claimed |
| EP-3941585-A1 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | Figene, LLC (US) | 2022-01-26 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133889-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | CXCR4 287/4885TFPI 1544/4885APLNR 1698/4885 |
| US-20250177303-A1 | A DRUG NANOCARRIER SYSTEM TO DELIVER A COMBINATION OF TLR AGONISTS AND/OR A LIPOXIN PLUS IMMUNOGENIC CELL DEATH INDUCING CHEMOTHERAPEUTIC AGENTS FOR CANCER IMMUNOTHERAPY | TLR7, TLR9, TLR8 | CXCR4 240/4885TFPI 4417/4885APLNR 428/4885 |
| US-20250275940-A1 | PTEROSTILBENE AND SILIBININ FOR PREVENTING, AMELIORATING OR REDUCING RADIATION-INDUCED DISEASES | SIRT1, SIRT2, SIRT3 | CXCR4 4251/4885TFPI 3141/4885APLNR 3770/4885 |
| US-20250213684-A1 | COMBINATION THERAPIES COMPRISING ANTIBODY MOLECULES TO TIM-3 | HAVCR2, LGALS3BP, CD274 | CXCR4 287/4885TFPI 1544/4885APLNR 1698/4885 |
| US-20220211866-A1 | MOMP TELONANOPARTICLES, AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | CETP, PCTP, MTTP | CXCR4 3209/4885TFPI 2680/4885APLNR 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.